Literature DB >> 6220077

Heterogeneity of an anti-H-2 I-A response as determined by cloned T cell reactivity.

A B Peck, R T Smith, M R Jadus.   

Abstract

T lymphocytes activated against the I-Aq gene product in primary mixed leukocyte culture (MLC) exhibit an unusually strong cross-reactivity against all third-party stimulating strains tested in secondary MLC. Through the development of anti-I-Aq clones, this cross-recognition has been shown to result from the activation of a heterogeneous T lymphocyte population bearing receptors that recognize the I-Aq gene product differently, yet specifically. The determination of functional activities of the anti-I-Aq cloned cells, e.g., lymphokine production and ability to induce lethal graft-vs-host disease, suggested even further heterogeneity in T cells grouped according to their similar cross-reactive pattern.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220077

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice.

Authors:  R Holmdahl; M Karlsson; M E Andersson; L Rask; L Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis.

Authors:  R Holmdahl; L Jansson; M Andersson; E Larsson
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

3.  Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T helper cell clones.

Authors:  P V Lehmann; G Schumm; D Moon; U Hurtenbach; F Falcioni; S Muller; Z A Nagy
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

4.  High antibody response to autologous type II collagen is restricted to H-2q.

Authors:  R Holmdahl; L Klareskog; M Andersson; C Hansen
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.